<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A066F1DD-B190-4AF8-BBDA-7140B0E1160E"><gtr:id>A066F1DD-B190-4AF8-BBDA-7140B0E1160E</gtr:id><gtr:firstName>Sue</gtr:firstName><gtr:surname>Bell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/06BF5533-1CCF-4843-81A2-F7D7DD0D10C5"><gtr:id>06BF5533-1CCF-4843-81A2-F7D7DD0D10C5</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>Robert</gtr:otherNames><gtr:surname>Singer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/91163B4E-C7F4-4D08-8666-8527EAAE0246"><gtr:id>91163B4E-C7F4-4D08-8666-8527EAAE0246</gtr:id><gtr:firstName>Julia</gtr:firstName><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FD0F80EE-81F5-419C-A56B-9F007162C894"><gtr:id>FD0F80EE-81F5-419C-A56B-9F007162C894</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:otherNames>Trehane</gtr:otherNames><gtr:surname>Drayson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/046B26F0-166F-4BC1-8BFE-25E67CB6F99C"><gtr:id>046B26F0-166F-4BC1-8BFE-25E67CB6F99C</gtr:id><gtr:firstName>Janine</gtr:firstName><gtr:surname>Gray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/333B689B-B1A1-414C-A520-C87F48B43704"><gtr:id>333B689B-B1A1-414C-A520-C87F48B43704</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:otherNames>Dilys</gtr:otherNames><gtr:surname>Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F6039BBB-9E6C-4E95-AD00-1937497E07F5"><gtr:id>F6039BBB-9E6C-4E95-AD00-1937497E07F5</gtr:id><gtr:firstName>Maxine</gtr:firstName><gtr:otherNames>Lesley</gtr:otherNames><gtr:surname>Stead</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9F381871-C656-432B-8159-7E93A8BA87E2"><gtr:id>9F381871-C656-432B-8159-7E93A8BA87E2</gtr:id><gtr:firstName>Gordon</gtr:firstName><gtr:surname>Cook</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/073AC073-13CA-4E61-BE3D-719561AA6719"><gtr:id>073AC073-13CA-4E61-BE3D-719561AA6719</gtr:id><gtr:firstName>G</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Morgan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/66DE6A52-9B76-44A2-8CDF-A1E2F9B8518A"><gtr:id>66DE6A52-9B76-44A2-8CDF-A1E2F9B8518A</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Child</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/57325399-7299-46CD-A73A-6EAD13DDDDDA"><gtr:id>57325399-7299-46CD-A73A-6EAD13DDDDDA</gtr:id><gtr:firstName>Graham</gtr:firstName><gtr:otherNames>Hunter</gtr:otherNames><gtr:surname>Jackson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0100132"><gtr:id>DF56FAD3-818E-43E3-87F3-F93D66F7ECC8</gtr:id><gtr:title>Myeloma IX Trial</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100132</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>This randomised controlled trial aims to evaluate whether thalidomide, together with induction therapy prolongs remission and overall survival, whether thalidomide in the maintenance setting prolongs remission and overall survival, whether the oral Z-Dex regimen is as effective an induction regimen as i.v. VAD with respect to survival and QOL, in younger/fitter patients, whether Z-Dex-C-weekly is as effective an induction/consolidation treatment as ?standard? chemotherapy (MP) with respect to survival and QOL, in older/less fit patients, and whether a second generation bisphosphonate (zoledronate) is superior to clodronate in inhibiting the bone changes in myeloma. In addition, the trial aims to assess whether the bisphosphonate exerts an antitumour effect in vivo, which translates into a survival benefit. 1600 patients will be randomised. The trial will comprise two groups of patients: younger/fitter and older/less fit. With the exception of the analysis of induction chemotherapy, the two groups will be combined for the primary comparisons. The primary end-points are remission rate, progression-free survival, relapse, survival. The secondary outcomes are quality of life and resource use. Protein studies, to include measurement of paraprotein (with immunofixation, as appropriate), and free light chains as objective measures of response, will be carried out centrally. Peripheral blood and bone marrow samples will be analysed centrally at presentation and at key specified time points, with in-depth assessment of responses using flow cytometry and PCR techniques. Patients will be followed up for five years, and then annually to death.</gtr:technicalSummary><gtr:fund><gtr:end>2014-07-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1940052</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Submitted data to NICE appraisal of thalidomide use in myeloma</gtr:description><gtr:geographicReach>UK</gtr:geographicReach><gtr:id>39F4680B-2D34-48CD-BF11-16C872B94011</gtr:id><gtr:impact>Thalidomide in combination with an alkylating agent and a corticosteroid is recommended as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>1. Therapeutic questions within the intensive pathway: 
1. 1. To compare an oral induction regimen containing thalidomide with a standard infusional induction chemotherapy, CTD versus CVAD, with respect to overall/progression-free survival and response. 
1.2. To investigate the effects of giving additional consolidation therapy in the form of a low intensity conditioning allogeneic stem cell transplantation on survival. 

2. Therapeutic questions within the non-intensive pathway: 
2.1. To compare attenuated C-Thal-Dex (CTDa) with standard MP with respect to overall/progression-free survival and response. 

3. Therapeutic questions across both pathways: 
3.1. To assess the value of low dose thalidomide in maintenance in improving overall and progression-free survival. 
3.2. To compare an aminobisphosphonate, zoledronic acid, with standard clodronate on the severity of bone disease and in improving survival. 
3.3. To investigate quality of life in the short-term (during induction chemotherapy/bisphosphonate treatment) and in the long-term (during maintenance therapy). 
3.4. To investigate prognostic factors for outcome. 

4. Biological objectives: 
4.1. To determine the clinical relevance of genetic/cytogenetic changes present at presentation in the definition of prognostic groups. 
4.2. To determine the relevance of cellular phenotypes at presentation and to subsequently use these data to monitor residual disease. 
4.3. To evaluate serum free light chain (flc) measurement as a prognostic factor and in monitoring disease.</gtr:description><gtr:id>A3776B6B-6138-46C0-AB0E-86519124D4D6</gtr:id><gtr:impact>Changed clinical practice, informed national guidelines, incorporated onto successor trial.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Myeloma IX</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN68454111</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/211792BF-1C59-4E90-BB5F-4FDE00144156"><gtr:id>211792BF-1C59-4E90-BB5F-4FDE00144156</gtr:id><gtr:title>Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80d44c908dacef25519ca398a536b2e2"><gtr:id>80d44c908dacef25519ca398a536b2e2</gtr:id><gtr:otherNames>Rawstron AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E2B14DC-E268-4DAD-9874-F7C3DBDB73FF"><gtr:id>0E2B14DC-E268-4DAD-9874-F7C3DBDB73FF</gtr:id><gtr:title>Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/47bbbad5d597f3a9225fb84758e10c0e"><gtr:id>47bbbad5d597f3a9225fb84758e10c0e</gtr:id><gtr:otherNames>Tapper W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3848D2F9-0618-45EC-8166-661BF3785CA6"><gtr:id>3848D2F9-0618-45EC-8166-661BF3785CA6</gtr:id><gtr:title>The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/363b76b050676f5bb8f3f482797f3dd4"><gtr:id>363b76b050676f5bb8f3f482797f3dd4</gtr:id><gtr:otherNames>Ross FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6595AFE2-852C-42B0-9F50-62BC44263344"><gtr:id>6595AFE2-852C-42B0-9F50-62BC44263344</gtr:id><gtr:title>Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Cancer epidemiology, biomarkers &amp; prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e6ea311a6e42dbcde073ac986fb177e6"><gtr:id>e6ea311a6e42dbcde073ac986fb177e6</gtr:id><gtr:otherNames>Boyd KD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1055-9965</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/026524D3-203B-4666-B3EB-596B05655CC8"><gtr:id>026524D3-203B-4666-B3EB-596B05655CC8</gtr:id><gtr:title>Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef1c2433aab66d079670774af33292af"><gtr:id>ef1c2433aab66d079670774af33292af</gtr:id><gtr:otherNames>Morgan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0E129380-94E0-4C2E-902B-9F8F5D87ED42"><gtr:id>0E129380-94E0-4C2E-902B-9F8F5D87ED42</gtr:id><gtr:title>Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/92756df9bb4d2f0a73e63c20a5e08de7"><gtr:id>92756df9bb4d2f0a73e63c20a5e08de7</gtr:id><gtr:otherNames>Jackson GH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7B0AC835-BDDF-4B58-B76B-32D7F585400A"><gtr:id>7B0AC835-BDDF-4B58-B76B-32D7F585400A</gtr:id><gtr:title>Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef1c2433aab66d079670774af33292af"><gtr:id>ef1c2433aab66d079670774af33292af</gtr:id><gtr:otherNames>Morgan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A49679F5-866A-45B6-A15A-A42DC5AC1ADE"><gtr:id>A49679F5-866A-45B6-A15A-A42DC5AC1ADE</gtr:id><gtr:title>Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/80d44c908dacef25519ca398a536b2e2"><gtr:id>80d44c908dacef25519ca398a536b2e2</gtr:id><gtr:otherNames>Rawstron AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03527873-2CA7-45FD-997E-6F34DF697A4B"><gtr:id>03527873-2CA7-45FD-997E-6F34DF697A4B</gtr:id><gtr:title>Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef1c2433aab66d079670774af33292af"><gtr:id>ef1c2433aab66d079670774af33292af</gtr:id><gtr:otherNames>Morgan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BF763158-DA25-4F25-A315-EE1055EF5839"><gtr:id>BF763158-DA25-4F25-A315-EE1055EF5839</gtr:id><gtr:title>First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef1c2433aab66d079670774af33292af"><gtr:id>ef1c2433aab66d079670774af33292af</gtr:id><gtr:otherNames>Morgan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE83706B-CCF4-4D8B-BDE4-3B73E4DFF00B"><gtr:id>FE83706B-CCF4-4D8B-BDE4-3B73E4DFF00B</gtr:id><gtr:title>High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma.</gtr:title><gtr:parentPublicationTitle>Leukemia &amp; lymphoma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e6ea311a6e42dbcde073ac986fb177e6"><gtr:id>e6ea311a6e42dbcde073ac986fb177e6</gtr:id><gtr:otherNames>Boyd KD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1026-8022</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BAF16B8B-3ECA-4C4D-B6CB-1954EC7660CA"><gtr:id>BAF16B8B-3ECA-4C4D-B6CB-1954EC7660CA</gtr:id><gtr:title>Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef1c2433aab66d079670774af33292af"><gtr:id>ef1c2433aab66d079670774af33292af</gtr:id><gtr:otherNames>Morgan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F68505E-A406-41BD-998A-1A20D571A001"><gtr:id>7F68505E-A406-41BD-998A-1A20D571A001</gtr:id><gtr:title>XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/908e4156df676a8f5c67350fba8b8e26"><gtr:id>908e4156df676a8f5c67350fba8b8e26</gtr:id><gtr:otherNames>Bagratuni T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB5263C0-F8CB-4B7A-83CE-75153DD64AC0"><gtr:id>BB5263C0-F8CB-4B7A-83CE-75153DD64AC0</gtr:id><gtr:title>A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.</gtr:title><gtr:parentPublicationTitle>Leukemia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e6ea311a6e42dbcde073ac986fb177e6"><gtr:id>e6ea311a6e42dbcde073ac986fb177e6</gtr:id><gtr:otherNames>Boyd KD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0887-6924</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/630C04A1-9C51-4712-B91B-0591D4059F9A"><gtr:id>630C04A1-9C51-4712-B91B-0591D4059F9A</gtr:id><gtr:title>A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2148ef93a115e61f1f350f3fd46d78d0"><gtr:id>2148ef93a115e61f1f350f3fd46d78d0</gtr:id><gtr:otherNames>Wu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/89F7D770-3C78-49B4-90BE-A22C1C03CFBF"><gtr:id>89F7D770-3C78-49B4-90BE-A22C1C03CFBF</gtr:id><gtr:title>Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b220d5581aee43d01f4d8053176db86"><gtr:id>1b220d5581aee43d01f4d8053176db86</gtr:id><gtr:otherNames>Walker BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B446F2C0-6780-428A-B7E5-DD61A4F066FD"><gtr:id>B446F2C0-6780-428A-B7E5-DD61A4F066FD</gtr:id><gtr:title>Improved risk stratification in myeloma using a microRNA-based classifier.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2148ef93a115e61f1f350f3fd46d78d0"><gtr:id>2148ef93a115e61f1f350f3fd46d78d0</gtr:id><gtr:otherNames>Wu P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2309B5FE-E13B-4B19-BC34-26028E636B66"><gtr:id>2309B5FE-E13B-4B19-BC34-26028E636B66</gtr:id><gtr:title>Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cbdedd225da521443b499b7da609ed1c"><gtr:id>cbdedd225da521443b499b7da609ed1c</gtr:id><gtr:otherNames>Johnson DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7280C984-BCF6-4EB2-95CE-173D06814797"><gtr:id>7280C984-BCF6-4EB2-95CE-173D06814797</gtr:id><gtr:title>Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef1c2433aab66d079670774af33292af"><gtr:id>ef1c2433aab66d079670774af33292af</gtr:id><gtr:otherNames>Morgan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF286388-5268-4032-AAF0-662C084A05D8"><gtr:id>EF286388-5268-4032-AAF0-662C084A05D8</gtr:id><gtr:title>Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f85064484c39e178b177bca3f79141ae"><gtr:id>f85064484c39e178b177bca3f79141ae</gtr:id><gtr:otherNames>Dickens NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A36C98B-4D54-4A0E-BEC7-B298BC457AA3"><gtr:id>1A36C98B-4D54-4A0E-BEC7-B298BC457AA3</gtr:id><gtr:title>The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ef1c2433aab66d079670774af33292af"><gtr:id>ef1c2433aab66d079670774af33292af</gtr:id><gtr:otherNames>Morgan GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB24D80E-F865-4CAE-A1EB-80B50F2AB848"><gtr:id>FB24D80E-F865-4CAE-A1EB-80B50F2AB848</gtr:id><gtr:title>The impact of response on bone-directed therapy in patients with multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9b3fb577497717cf8bdd4d599be6261e"><gtr:id>9b3fb577497717cf8bdd4d599be6261e</gtr:id><gtr:otherNames>Larocca A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/877782B1-78B9-4577-AA98-27D3EE9752E7"><gtr:id>877782B1-78B9-4577-AA98-27D3EE9752E7</gtr:id><gtr:title>Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/67147ecd89ac5990ec78fc3ef22de02d"><gtr:id>67147ecd89ac5990ec78fc3ef22de02d</gtr:id><gtr:otherNames>de Tute RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C186AE3-0265-4841-98EC-E2545691D74E"><gtr:id>8C186AE3-0265-4841-98EC-E2545691D74E</gtr:id><gtr:title>A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b220d5581aee43d01f4d8053176db86"><gtr:id>1b220d5581aee43d01f4d8053176db86</gtr:id><gtr:otherNames>Walker BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/502F2B71-EA13-49BE-B855-6275FABC447E"><gtr:id>502F2B71-EA13-49BE-B855-6275FABC447E</gtr:id><gtr:title>Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1b220d5581aee43d01f4d8053176db86"><gtr:id>1b220d5581aee43d01f4d8053176db86</gtr:id><gtr:otherNames>Walker BA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD7E113D-6609-4947-9E33-5252FF424F0E"><gtr:id>FD7E113D-6609-4947-9E33-5252FF424F0E</gtr:id><gtr:title>Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cbdedd225da521443b499b7da609ed1c"><gtr:id>cbdedd225da521443b499b7da609ed1c</gtr:id><gtr:otherNames>Johnson DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100132</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>